SCHEMBL17809804

SCHEMBL17809804

Cc1ccc(-c2cnn(CCN(C)C)c2)cc1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TGFBR1 P36897 8/20 0.53
MAP4K4 O95819 5/20 0.53
KCNH2 Q12809 3/20 0.44
FLT3 P36888 2/20 0.44
LRRK2 Q5S007 1/20 0.44
BRD4 O60885 1/20 0.43
CREBBP Q92793 1/20 0.43
KDR P35968 1/20 0.43
EPHB4 P54760 1/20 0.43
TEK Q02763 1/20 0.43
CDK8 P49336 1/20 0.42
CDK19 Q9BWU1 1/20 0.42
CYP2D6 P10635 1/20 0.42
CYP2C9 P11712 1/20 0.42
ALOX5AP P20292 1/20 0.42
JAK2 O60674 1/20 0.41
JAK1 P23458 1/20 0.41
TYK2 P29597 1/20 0.41
JAK3 P52333 1/20 0.41
GRIN2B Q13224 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17806512 0.83 TGFBR1 (0.55) TGFBR1MAP4K4KCNH2FLT3BRD4
SCHEMBL13036117 0.81 PIK3CD (0.51) KCNH2LRRK2KDREPHB4TEK
SCHEMBL21601373 0.80 LRRK2 (0.46) KCNH2LRRK2CREBBPKDREPHB4
SCHEMBL10195600 0.80 NAMPT (0.49) MAP4K4KCNH2LRRK2BRD4CREBBP
SCHEMBL12093594 0.79 LMNA (0.39) TGFBR1MAP4K4FLT3CYP2D6CYP2C9
SCHEMBL17809809 0.78 LRRK2 (0.64) KCNH2LRRK2CREBBPKDREPHB4
SCHEMBL2082437 0.77 NAMPT (0.52) KCNH2LRRK2KDREPHB4TEK
SCHEMBL17809806 0.77 CREBBP (0.44) TGFBR1MAP4K4KCNH2LRRK2BRD4
SCHEMBL25415742 0.77 JAK2 (0.47) TGFBR1MAP4K4KCNH2FLT3CREBBP
SCHEMBL22792379 0.75 JAK2 (0.43) TGFBR1MAP4K4FLT3BRD4CREBBP

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3224258-B1 4,5,6,7-TETRAHYDRO-1H-PYRAZOLO[4,3-C]PYRIDIN-3-AMINE COMPOUNDS AS CBP AND/OR EP300 INHIBITORS GENENTECH INC (US) 2019-08-14 EP disclosed
US-9763922-B2 Therapeutic compounds and uses thereof GENENTECH, INC. (US) 2017-09-19 US disclosed
US-20160158207-A1 THERAPEUTIC COMPOUNDS AND USES THEREOF GENENTECH, INC. (US) 2016-06-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160158207-A1 THERAPEUTIC COMPOUNDS AND USES THEREOF EP300, HDAC1, HDAC10 TGFBR1 1202/4885MAP4K4 1287/4885KCNH2 2291/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.